Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Chewy investor day underwhelms, 'not thesis changing' says analysts

Published 12/15/2023, 09:00 AM
Updated 12/15/2023, 09:04 AM
© Reuters.  Chewy (CHWY) investor day underwhelms, 'not thesis changing' says analyst

Online pet retailer Chewy's (NYSE:CHWY) shares are up more than 3% ahead of the open on Friday, a day after the company held an investor day, with Wall Street analysts providing a mixed reaction to the event.

The company reportedly discussed key initiatives across health, retail, international, operations, and updated its financial framework and long-term targets.

BofA analysts maintained an Underperform rating and $15 price target on the stock following the investor day, stating that the targets Chewy unveiled at the event were largely underwhelming.

"Overall, we think targets underwhelmed investor expectations, with Chewy targeting just HSD% long-term growth (vs. industry at 5-7% CAGR) and 10%+ EBITDA margins, though relatively limited improvement in OPEX (+3pts potential leverage) and seemingly a long-time horizon on gross margin expansion," analysts said.

JMP Securities maintained an Outperform rating and a $28 price target on the stock. Analysts said management described the financial profile of the company as being at an inflection point, and they expect an average 15% annual adjusted EBITDA flow-through in FY24 and beyond.

"We believe updated long-term targets were slightly below to in line with expectations, particularly on LT, adjusted EBITDA margin targets," analysts said. "We did not view the analyst day as thesis changing and walked away impressed with its improving operational efficiencies, driven by automation initiatives, and consistent cohort behavior driving predictable LTV/CAC trends."

Evercore ISI analysts were slightly more positive following the event, saying that overall, they came away with greater clarity on the
key drivers supporting the next 700bps of EBITDA Margin expansion.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"We continue to like the story longer term as new growth initiatives like Health, Ads, other pet services, and international expansion starts to scale, and valuations may well start to look interesting if we start to see more meaningful EBTIDA Margin ramp-up," analysts said, who kept an In line rating and $19 price target on the stock.

"Near term, we remain on the sidelines as the muted Pet industry outlook continues to put a damper on user growth, which we think is likely to persist into next year," they added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.